Nurix Therapeutics, Inc. (NRIX)
Drugs • Health Care
July 21, 2026 Nurix Therapeutics Secures HSR Clearance for Major Collaboration with Roche Nurix Therapeutics has finalized a collaboration with Roche to co-develop bexobrutideg, a BTK degrader, promising advancements in oncology and immunology. The agreement includes a $700 million upfront payment and potential earnings up to $2.3 billion, positioning Nurix to accelerate its clinical development efforts.
July 09, 2026 Nurix Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Developments Nurix Therapeutics reported a revenue decline in Q2 2026, attributed to prior license revenue. The company announced a significant partnership with Roche to co-develop bexobrutideg, aimed at treating various malignancies and autoimmune diseases, alongside promising clinical trial results.
July 09, 2026 Nurix Therapeutics, Inc. Reports Dismal Q2 2026 Results Amid Strategic Collaborations and Clinical Advancements Nurix Therapeutics reported significant financial challenges in Q2 2026, with a net loss of $89.53 million. However, strategic collaborations with major biopharmaceutical companies and advancements in their clinical pipeline provide a glimmer of hope for recovery and growth.
June 11, 2026 Nurix Therapeutics Reports Promising Phase 1a/b Results for Bexobrutideg in CLL/SLL Patients Nurix Therapeutics revealed promising Phase 1a/b trial results for bexobrutideg, a BTK degrader, showing high efficacy in CLL/SLL patients, including those with treatment resistance. The drug demonstrates a strong safety profile and potential to redefine BTK-directed therapy.
June 08, 2026 Nurix Therapeutics and Roche Forge Strategic Alliance to Develop Innovative BTK Degrader Nurix Therapeutics has partnered with Roche to co-develop bexobrutideg, an innovative BTK degrader targeting blood cancers and immune diseases. This collaboration aims to enhance treatment efficacy through a unique degradation mechanism. The alliance will also support extensive clinical trials across various therapeutic areas.
May 14, 2026 Nurix Therapeutics Unveils Promising Data on Bexobrutideg at 2026 Society for Investigative Dermatology Annual Meeting Nurix Therapeutics showcased promising data on bexobrutideg, a novel BTK degrader, at the 2026 SID Annual Meeting. The findings indicate its superior efficacy in treating chronic spontaneous urticaria compared to traditional BTK inhibitors, paving the way for innovative treatments in autoimmune diseases.
April 22, 2026 Nurix Therapeutics Unveils Promising Preclinical Data at AACR 2026 Nurix Therapeutics unveiled significant preclinical data at AACR 2026, showcasing advancements in targeted protein degradation therapies for cancer. Key highlights include the efficacy of NRX-0305 in BRAF mutations and innovative approaches to boost T cell activation with NX-1607.
April 08, 2026 Nurix Therapeutics Reports First Quarter 2026 Financial Results and Corporate Update Nurix Therapeutics reported significant financial updates for Q1 2026, highlighting advancements in its lead program, bexobrutideg, and ongoing clinical trials. The company faces a net loss but continues to invest in its promising drug pipeline aimed at treating CLL and other malignancies.
April 08, 2026 Nurix Therapeutics Reports Q1 2026 Financial Results: A Deep Dive into Challenges and Opportunities Nurix Therapeutics reports a net loss of $87.2 million in Q1 2026, reflecting increased R&D expenses. Despite financial challenges, strategic collaborations and a promising drug pipeline position the company for future growth.
April 07, 2026 Nurix Therapeutics Engages Investors at Needham Virtual Healthcare Conference Nurix Therapeutics will participate in the Needham Virtual Healthcare Conference, featuring a discussion with CEO Dr. Arthur T. Sands on targeted protein degradation. The event promises key insights into the company's innovative pipeline and strategic collaborations in drug development.
March 23, 2026 Nurix Therapeutics Showcases Cutting-Edge Research at AACR 2026 Annual Meeting Nurix Therapeutics will showcase its cutting-edge cancer research at the AACR 2026 Annual Meeting, featuring key presentations on innovative drug candidates. The company emphasizes targeted protein degradation with promising results for various cancer types. Their investigational drugs, including NX-1607 and NRX-4972, aim to transform treatment outcomes for patients.
January 28, 2026 Nurix Therapeutics Reports Strong Q4 and Fiscal Year 2025 Financial Results Nurix Therapeutics announced strong financial results for Q4 and fiscal year 2025, with revenue growth driven by collaborations. The company is advancing its clinical pipeline, particularly bexobrutideg, and has a solid cash position to support future initiatives.
January 28, 2026 Nurix Therapeutics, Inc. Reports 2025 Annual Results: A Year of Progress Amidst Challenges Nurix Therapeutics, Inc. reports significant progress in its 2025 annual results, highlighting advancements in its clinical pipeline and strategic partnerships. Despite financial losses, the company remains optimistic about its innovative therapies targeting cancer and inflammatory diseases.
January 12, 2026 Nurix Therapeutics Sets Ambitious Goals for 2026 in Cancer and Autoimmune Disease Treatment Nurix Therapeutics has set ambitious goals for 2026, highlighting its lead product bexobrutideg for cancer treatment and advancements in autoimmune therapies. The company aims to execute pivotal trials and expand its innovative pipeline, positioning itself as a leader in targeted protein degradation.
January 05, 2026 Nurix Therapeutics Set to Present at 44th Annual J.P. Morgan Healthcare Conference Nurix Therapeutics will present at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026. The company focuses on innovative therapies targeting protein degradation, with notable collaborations and a robust clinical pipeline aimed at cancer and autoimmune diseases.
December 08, 2025 Promising Results for Nurix Therapeutics' Bexobrutideg Presented at 2025 ASH Annual Meeting Nurix Therapeutics showcased favorable Phase 1 trial results for bexobrutideg in relapsed Waldenström macroglobulinemia at the ASH 2025 meeting. The drug demonstrated a 75% objective response rate and a favorable safety profile, indicating its potential as a transformative therapy.
December 06, 2025 Nurix Therapeutics Unveils Promising Phase 1 Data for Bexobrutideg in Chronic Lymphocytic Leukemia Nurix Therapeutics presented promising Phase 1 data for Bexobrutideg at the ASH Annual Meeting, showing an 83% response rate in relapsed CLL patients. The drug demonstrated a strong safety profile and offers hope for patients with limited treatment options.
December 01, 2025 Nurix Therapeutics to Present New Data on Bexobrutideg at ASH Annual Meeting Nurix Therapeutics will present new data on its investigational BTK degrader, bexobrutideg, during a live webcast on December 8, 2025, ahead of the ASH Annual Meeting. The event will feature insights from key experts, including Dr. Alvaro Alencar, and updates on Nurix's clinical strategies.
November 25, 2025 Nurix Therapeutics to Showcase Innovations at Piper Sandler Healthcare Conference Nurix Therapeutics will showcase its innovations at the Piper Sandler Conference, highlighting its focus on targeted protein degradation in drug development. The event features a fireside chat with key leaders, discussing the company’s strategic direction and pipeline advancements.
November 10, 2025 Nurix Therapeutics Welcomes Roger Dansey, M.D., to Board of Directors Nurix Therapeutics has appointed Dr. Roger Dansey to its board of directors, leveraging his extensive experience in oncology to enhance its drug development efforts. This strategic move aims to advance the company’s clinical trials and innovative therapies for cancer and autoimmune diseases.
November 07, 2025 Nurix Therapeutics Unveils Promising Data on Oral CBL-B Inhibitor NX-1607 at SITC 2025 Nurix Therapeutics unveiled significant data on NX-1607, a CBL-B inhibitor, at SITC 2025, highlighting its potential in boosting immune responses in cancer patients. The findings show dose-dependent pharmacologic activity and immune activation, particularly in patients with stable disease.
November 03, 2025 Nurix Therapeutics Unveils Promising Clinical Data Ahead of ASH 2025 Nurix Therapeutics will present crucial clinical data on its investigational drug NX-5948 at the ASH 2025 conference, highlighting its effectiveness in treating Chronic Lymphocytic Leukemia and Waldenström Macroglobulinemia. The presentations will provide insights into the drug's clinical responses and resistance mechanisms targeting Bruton's tyrosine kinase.
October 30, 2025 Nurix Therapeutics Set to Make Waves at November Investor Conferences Nurix Therapeutics is set to participate in two prominent investor conferences in November 2025, highlighting its advancements in targeted protein degradation. CEO Arthur T. Sands will discuss the company’s innovative therapies aimed at cancer and inflammatory diseases, alongside its strategic partnerships with industry leaders.
October 27, 2025 Nurix Therapeutics Secures $250 Million in Common Stock Offering Nurix Therapeutics has successfully raised $250 million through a stock offering to boost its clinical development efforts for chronic lymphocytic leukemia (CLL) and explore new treatments for autoimmune diseases. The funding highlights strong investor interest and positions Nurix as a leader in targeted protein degradation therapies.
October 22, 2025 Nurix Therapeutics Secures $250 Million in Registered Common Stock Offering Nurix Therapeutics has announced a $250 million registered stock offering aimed at funding its clinical developments, including treatments for CLL. The offering has garnered significant interest from investors, emphasizing confidence in Nurix's innovative approach to drug development.
October 22, 2025 Nurix Therapeutics Launches Pivotal DAYBreak™ Study for Bexobrutideg in CLL Nurix Therapeutics has launched the DAYBreak clinical trial to evaluate the efficacy of bexobrutideg in patients with relapsed or refractory chronic lymphocytic leukemia. This pivotal Phase 2 study is supported by previous positive data and aims to address significant unmet needs in CLL treatment. With regulatory alignment and plans for a Phase 3 trial, Nurix is positioned to potentially redefine CLL therapies.
October 18, 2025 Nurix Therapeutics Unveils Promising Clinical Data on NX-1607 at ESMO 2025 Nurix Therapeutics presented positive clinical data on its investigational drug NX-1607 at ESMO 2025. The Phase 1a trial showed significant tumor reduction and a 49.3% disease control rate in patients with relapsed solid tumors. The drug demonstrated a favorable safety profile and potential for treating resistant cancers.
October 09, 2025 Nurix Therapeutics, Inc. Reports Q3 2025 Financial Results: A Closer Look at Innovation Amid Financial Challenges Nurix Therapeutics reported significant operating losses in Q3 2025 amid ongoing investments in its drug pipeline. The company faces challenges with escalating costs but maintains a strong focus on innovative therapies for cancer and autoimmune diseases.
October 09, 2025 Nurix Therapeutics Reports Promising Developments and Financial Results for Q3 2025 Nurix Therapeutics reported its Q3 2025 financial results, highlighting significant advancements in its drug pipeline, particularly for bexobrutideg in CLL. Despite a revenue decline, optimistic trial results and strong cash reserves position the company for future growth.
July 09, 2025 Nurix Therapeutics, Inc. Reports 2025 Q2 Results: A Mixed Bag of Progress and Challenges Nurix Therapeutics, Inc. reported a significant revenue increase in Q2 2025, driven by strategic collaborations, but faced ongoing financial challenges with a notable net loss and rising expenses. The company's drug candidates are progressing through trials, highlighting both advancements and the complexities of the biopharmaceutical landscape.
April 08, 2025 Nurix Therapeutics Reports Q1 2025 Financial Results: Navigating Innovation Amidst Losses Nurix Therapeutics reported a net loss of $56.4 million for Q1 2025, with increased revenue of $18.45 million. Despite rising operational costs, the company is advancing its clinical trials for promising therapies like bexobrutideg, supported by strategic partnerships.
April 02, 2025 Nurix Therapeutics and Sanofi Forge Innovative Alliance for Autoimmune Disease Treatment Nurix Therapeutics has formed an exclusive licensing agreement with Sanofi to develop new treatments for autoimmune diseases targeting a previously undruggable transcription factor. This collaboration enhances Nurix's drug discovery capabilities and highlights their innovative DEL-AI platform, paving the way for significant advancements in patient care.
March 25, 2025 Nurix Therapeutics Showcases Breakthroughs at AACR 2025 Annual Meeting Nurix Therapeutics will present groundbreaking research at the AACR 2025 Annual Meeting, highlighting their DEL-AI platform and targeted protein degraders for cancer. Key presentations include advancements in drug discovery using AI and new treatments for pediatric and adult cancers.
March 17, 2025 Nurix Therapeutics Secures FDA Orphan Drug Designation for Bexobrutideg in Waldenström Macroglobulinemia Treatment Nurix Therapeutics has received FDA Orphan Drug Designation for bexobrutideg, an innovative treatment for Waldenström macroglobulinemia. This designation supports the development of therapies targeting rare diseases, reinforcing the need for improved treatment options in this field.
March 14, 2025 Nurix Therapeutics Strengthens Workforce with Inducement Grants Nurix Therapeutics has issued inducement grants to thirteen new employees as part of its strategy to attract top talent. These grants include stock options and RSUs, aimed at bolstering the company's drug development capabilities, particularly in cancer and inflammatory diseases.
March 13, 2025 Nurix Therapeutics Welcomes Roy D. Baynes to Its Board of Directors Nurix Therapeutics has appointed Dr. Roy D. Baynes to its board of directors, bringing over 22 years of experience in drug development. His expertise in oncology will be vital as Nurix advances its innovative therapies targeting diseases like chronic lymphocytic leukemia.
March 04, 2025 Nurix Therapeutics to Showcase Innovations at Upcoming Investor Conferences Nurix Therapeutics is set to participate in two major investor conferences this March, highlighting its pioneering work in targeted protein degradation for cancer treatment. With a strong pipeline and strategic collaborations, the company aims to engage stakeholders and showcase its commitment to innovative therapies.
February 14, 2025 Nurix Therapeutics Grants Inducement Awards to New Employees Nurix Therapeutics has announced inducement awards for nine new employees to foster talent acquisition as part of its growth strategy. These awards include stock options and restricted stock units, aimed at advancing the company's innovative pipeline in targeted therapies for cancer and inflammatory diseases.
February 01, 2025 SWOT Analysis of Nurix Therapeutics, Inc. in 2025 This article provides a detailed SWOT analysis of Nurix Therapeutics, Inc. in 2025, highlighting its strong clinical pipeline and strategic partnerships, while also addressing financial challenges and competitive threats. The analysis underscores the company's potential for growth through innovative therapies and collaborations.
January 28, 2025 Nurix Therapeutics, Inc. Reports 2024 Annual Results: A Year of Challenges and Opportunities Nurix Therapeutics' 2024 annual report reveals a decline in revenue amidst significant clinical advancements in its drug pipeline. Despite financial challenges, the company continues to innovate and build strategic partnerships, aiming for operational efficiency and future growth.
October 11, 2024 Nurix Therapeutics, Inc. Reports Q3 2024 Financial Results: Navigating Challenges and Opportunities Nurix Therapeutics reports Q3 2024 financial results amid operational challenges, revealing a focus on advancing its clinical pipeline and strategic partnerships. Despite a net loss, the company maintains strong liquidity and growth in assets, positioning itself well for future developments.
July 11, 2024 Nurix Therapeutics, Inc. Reports Promising Q2 2024 Results Amidst Strategic Collaborations Nurix Therapeutics, Inc. has reported its Q2 2024 financial results, showcasing a decline in total revenue but significant collaboration gains. The company remains financially strong with $452.5 million in liquidity, positioning itself for future growth despite ongoing operational losses.
April 10, 2024 Nurix Therapeutics, Inc. Reports Q1 2024 Financial Results: Growth Amidst Losses Nurix Therapeutics, Inc. reported a revenue increase to $16.58 million in Q1 2024, driven by collaboration revenues despite rising R&D expenses leading to a net loss of $41.5 million. The company continues to invest in its drug pipeline and strategic partnerships, indicating potential for future growth.